Abaloparatide is a biopharmaceutical product produced by living cell expression systems, whose pharmacological activity arises from specific binding interactions with biological targets including cell-surface receptors, soluble cytokines, or enzyme active sites. The manufacturing process—encompassing upstream cell culture, downstream purification, and formulation—is intrinsically linked to product quality and must be validated to ensure consistent structure and potency. PDE assessment for biological compounds focuses on on-target pharmacological hazard, with occupational inhalation exposure to protein aerosols during fill-finish operations representing the primary manufacturing exposure concern.
The pharmacologically-based OEL approach is used for Abaloparatide when its receptor-mediated pharmacodynamic activity in humans produces the most sensitive adverse effect at doses below the NOAEL from general organ toxicity studies.
